1. Chemotherapy-induced peripheral neuropathies in hematological malignancies

   • Joost Louis Marie Jongen
   • Annemiek Broijl
   • Pieter Sonneveld

   Topic Review 19 October 2014 Pages: 229 - 237

   

2. Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells

   • Shingo Tanaka
   • Mitsutoshi Nakada
   • Atsushi Hirao

   Laboratory Investigation 08 October 2014 Pages: 239 - 250

   

3. PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment

   • Dimitrios Mathios
   • Jacob Ruzevick
   • Michael Lim

   Laboratory Investigation 28 October 2014 Pages: 251 - 259

   

4. The expression of SALL4 in patients with gliomas: high level of SALL4 expression is correlated with poor outcome

   • Lei Zhang
   • Yong Yan
   • Xiaojun Wu

   Laboratory Investigation 31 October 2014 Pages: 261 - 268

   

5. Lack of evidence for PlGF mediating the tumor resistance after anti-angiogenic therapy in malignant gliomas

   • Kristin Schneider
   • Astrid Weyerbrock
   • Marcia Regina Machein

   Laboratory Investigation 05 November 2014 Pages: 269 - 278

   

6. Mst1 regulates glioma cell proliferation via the AKT/mTOR signaling pathway

   • Yuewen Chao
   • Yan Wang
   • Xiuping Zhou

   Laboratory Investigation 06 November 2014 Pages: 279 - 288

   

7. Differential expression of Toll-like receptor (TLR) and B cell receptor (BCR) signaling molecules in primary diffuse large B-cell lymphoma of the central nervous system

   • Ariz Akhter
   • Noraidah Masir
   • Adnan Mansoor

   Laboratory Investigation 13 November 2014 Pages: 289 - 296

   

8. Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas

   • Andrew D. Norden
   • David Schiff
   • Patrick Y. Wen

   Clinical Study 22 October 2014 Pages: 297 - 302

   

9. Pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT: does it have a place in predicting survival in patients with glioblastoma multiforme?

   • Amr Amin
   • M. Mustafa
   • E. Saad

   Clinical Study 28 October 2014 Pages: 303 - 309

   

10. Outcome of radiosurgery for recurrent malignant gliomas: assessment of treatment response using relative cerebral blood volume

    • Hong Rye Kim
    • Se-Hwan Kim
    • Doo-Sik Kong

    Clinical Study 09 December 2014 Pages: 311 - 318

    

11. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme

    • Martin K. Hunn
    • Evelyn Bauer
    • Ian F. Hermans

    Clinical Study 31 October 2014 Pages: 319 - 329

    

12. Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab

    • Qiuting Wen
    • Laleh Jalilian
    • Sarah J. Nelson

    Clinical Study Open access 29 October 2014 Pages: 331 - 339

    

13. Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2

    • Tobias Walbert
    • Tito R. Mendoza
    • Terri S. Armstrong

    Clinical Study 31 October 2014 Pages: 341 - 348

14. Classification of tumor area using combined DCE and DSC MRI in patients with glioblastoma

    • Moran Artzi
    • Deborah T. Blumenthal
    • Dafna Ben Bashat

    Clinical Study 05 November 2014 Pages: 349 - 357

    

15. The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme

    • Lola B. Chambless
    • Heather M. Kistka
    • Reid C. Thompson

    Clinical Study 26 October 2014 Pages: 359 - 364

    

16. Treatment of large low-grade oligodendroglial tumors with upfront procarbazine, lomustine, and vincristine chemotherapy with long follow-up: a retrospective cohort study with growth kinetics

    • Walter Taal
    • Carin C. D. van der Rijt
    • Martin J. van den Bent

    Clinical Study 26 October 2014 Pages: 365 - 372

    

17. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab

    • Philipp Kickingereder
    • Benedikt Wiestler
    • Alexander Radbruch

    Clinical Study 31 October 2014 Pages: 373 - 380

    

18. Expert-validated CSF segmentation of MNI atlas enhances accuracy of virtual glioma growth patterns

    • A. Amelot
    • E. Stretton
    • E. Mandonnet

    Clinical Study 05 November 2014 Pages: 381 - 387

    

19. Tumor control and QoL outcomes of very young children with atypical teratoid/rhabdoid Tumor treated with focal only chemo-radiation therapy using pencil beam scanning proton therapy

    • Damien C. Weber
    • Carmen Ares
    • Ralf Schneider

    Clinical Study 02 November 2014 Pages: 389 - 397

    

20. Post progression survival in glioblastoma: where are we?

    • Enrico Franceschi
    • Mario Ermani
    • Alba A. Brandes

    Clinical Study 01 November 2014 Pages: 399 - 404

    

21. Single agent vinorelbine in pediatric patients with progressive optic pathway glioma

    • Andrea Maria Cappellano
    • Antonio Sergio Petrilli
    • Eric Bouffet

    Clinical Study 01 November 2014 Pages: 405 - 412

    

22. Pediatric supratentorial high-grade glioma: multicenter retrospective observational study of the Korean Society for Pediatric Neuro-Oncology

    • Tae-Young Jung
    • Ji Yeoun Lee
    • Seung-Ki Kim

    Clinical Study 04 November 2014 Pages: 413 - 419

    

23. Diffusion weighted MRI is a promising imaging biomarker in brain metastases

    • R. Zakaria
    • M. D. Jenkinson

    Letter to the Editor Open access 30 October 2014 Pages: 421 - 422

24. Comment on “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460]

    • Thomas C. Booth
    • Adam D. Waldman
    • Rolf Jäger

    Letter to the Editor 01 November 2014 Pages: 423 - 424